S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
"This Could be the Biggest Stock Story of 2023" (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
New Breakthrough "Living Software" Has Been… (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
"This Could be the Biggest Stock Story of 2023" (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
New Breakthrough "Living Software" Has Been… (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
"This Could be the Biggest Stock Story of 2023" (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
New Breakthrough "Living Software" Has Been… (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
"This Could be the Biggest Stock Story of 2023" (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
New Breakthrough "Living Software" Has Been… (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
NASDAQ:MDXH

MDxHealth (MDXH) Stock Forecast, Price & News

$2.73
+0.04 (+1.49%)
(As of 09/22/2023 ET)
Compare
Today's Range
$2.66
$2.81
50-Day Range
$2.70
$3.82
52-Week Range
$2.47
$8.51
Volume
12,721 shs
Average Volume
68,723 shs
Market Capitalization
$73.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

MDxHealth MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
193.0% Upside
$8.00 Price Target
Short Interest
Healthy
0.14% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.44) to ($1.08) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.86 out of 5 stars

Medical Sector

710th out of 963 stocks

Medical Laboratories Industry

16th out of 23 stocks


MDXH stock logo

About MDxHealth (NASDAQ:MDXH) Stock

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

MDXH Price History

MDXH Stock News Headlines

BTIG Sticks to Its Buy Rating for MDxHealth S.A. Sponsored ADR (MDXH)
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
MDxHealth Reports Q2 and Half Year 2023 Results
O6C0.MU - MDxHealth SA
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk
I recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.
mdxhealth: MDxHealth Reports Q1-2023 Results
MDxHealth Reports Q1-2023 Results
MDxHealth earnings preview: what Wall Street is expecting
Short Volatility Alert: Mdxhealth
Foundational LCD Covers Select mdx for Prostate Cancer
See More Headlines
Receive MDXH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MDxHealth and its competitors with MarketBeat's FREE daily newsletter.

MDXH Company Calendar

Last Earnings
8/23/2023
Today
9/24/2023
Next Earnings (Estimated)
10/26/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MDXH
Fax
N/A
Employees
252
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+193.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-44,040,000.00
Pretax Margin
-118.86%

Debt

Sales & Book Value

Annual Sales
$37.05 million
Book Value
$0.57 per share

Miscellaneous

Free Float
26,578,000
Market Cap
$73.82 million
Optionable
Not Optionable
Beta
0.30
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Michael K. McGarrity (Age 60)
    CEO & Exec. Director
    Comp: $571.37k
  • Mr. Ron Kalfus (Age 49)
    Chief Financial Officer
  • Mr. Joseph Sollee (Age 58)
    Exec. VP of Corp. Devel. & Gen. Counsel
  • Mr. John A. Bellano (Age 54)
    Chief Commercial Officer
  • Ms. Miriam Reyes (Age 50)
    Exec. VP of Operations
  • Dr. Wim Van Criekinge (Age 51)
    Chief Scientific Officer













MDXH Stock - Frequently Asked Questions

Should I buy or sell MDxHealth stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MDxHealth in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MDXH shares.
View MDXH analyst ratings
or view top-rated stocks.

What is MDxHealth's stock price forecast for 2023?

3 Wall Street analysts have issued 1 year price targets for MDxHealth's stock. Their MDXH share price forecasts range from $7.00 to $10.00. On average, they expect the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 193.0% from the stock's current price.
View analysts price targets for MDXH
or view top-rated stocks among Wall Street analysts.

How have MDXH shares performed in 2023?

MDxHealth's stock was trading at $6.61 at the start of the year. Since then, MDXH shares have decreased by 58.7% and is now trading at $2.73.
View the best growth stocks for 2023 here
.

Are investors shorting MDxHealth?

MDxHealth saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 35,200 shares, a decline of 59.7% from the August 15th total of 87,300 shares. Based on an average daily trading volume, of 95,000 shares, the short-interest ratio is currently 0.4 days. Currently, 0.1% of the company's shares are short sold.
View MDxHealth's Short Interest
.

When is MDxHealth's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our MDXH earnings forecast
.

How were MDxHealth's earnings last quarter?

MDxHealth SA (NASDAQ:MDXH) released its quarterly earnings results on Wednesday, August, 23rd. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.02. The firm had revenue of $16.75 million for the quarter, compared to the consensus estimate of $15.14 million. MDxHealth had a negative net margin of 87.00% and a negative trailing twelve-month return on equity of 203.05%.

What guidance has MDxHealth issued on next quarter's earnings?

MDxHealth issued an update on its FY 2023 earnings guidance on Thursday, August, 24th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $65.00 million-$70.00 million, compared to the consensus revenue estimate of $65.30 million.

When did MDxHealth IPO?

(MDXH) raised $45 million in an IPO on Thursday, November 4th 2021. The company issued 3,750,000 shares at $12.00 per share.

What is MDxHealth's stock symbol?

MDxHealth trades on the NASDAQ under the ticker symbol "MDXH."

Who are MDxHealth's major shareholders?

MDxHealth's stock is owned by many different institutional and retail investors. Top institutional investors include Perkins Capital Management Inc. (1.49%), Sei Investments Co. (0.75%), Renaissance Technologies LLC (0.11%), Citadel Advisors LLC (0.08%) and BerganKDV Wealth Management LLC (0.04%).
View institutional ownership trends
.

How do I buy shares of MDxHealth?

Shares of MDXH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MDxHealth's stock price today?

One share of MDXH stock can currently be purchased for approximately $2.73.

How much money does MDxHealth make?

MDxHealth (NASDAQ:MDXH) has a market capitalization of $73.82 million and generates $37.05 million in revenue each year. The company earns $-44,040,000.00 in net income (profit) each year or ($1.50) on an earnings per share basis.

How many employees does MDxHealth have?

The company employs 252 workers across the globe.

How can I contact MDxHealth?

MDxHealth's mailing address is CAP Business Center, Herstal, Liege 4040. The official website for the company is mdxhealth.com. The company can be reached via phone at 324-364-2070 or via email at ir@mdxhealth.com.

This page (NASDAQ:MDXH) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -